Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASP1570 |
| Synonyms | |
| Therapy Description |
ASP1570 is a DGKzeta inhibitor, which potentially reduces tumor cell proliferation and tumor growth (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASP1570 | ASP-1570|ASP 1570 | DGKZ Inhibitor 4 | ASP1570 is a DGKzeta inhibitor, which potentially reduces tumor cell proliferation and tumor growth (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05083481 | Phase Ib/II | ASP1570 + Pembrolizumab ASP1570 ASP1570 + Trifluridine-tipiracil hydrochloride ASP1570 + Docetaxel ASP1570 + Fluorouracil + Leucovorin + Oxaliplatin ASP1570 + Carboplatin + Pembrolizumab + Pemetrexed Disodium ASP1570 + Fluorouracil + Irinotecan + Leucovorin | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | Recruiting | USA | FRA | ESP | 4 |